FeesSafety
Pluang+

Tyra Biosciences faces investigation after adverse events in cancer drug trial cause stock to drop 17.66%.

Market News
08 Oct 2026, 17:00 WIB
PRNewsWire
View Source
Bearish
Tyra Biosciences faces investigation after adverse events in cancer drug trial cause stock to drop 17.66%.

Tyra Biosciences is under investigation by Pomerantz LLP for potential securities fraud following the release of Phase 2 trial results for its cancer drug dabogratinib. The trial showed a favorable safety profile but reported serious adverse events in 14% and 9% of patients at different doses. After the announcement, Tyra's stock price fell sharply by 17.66%. The investigation will determine if the company or its officers engaged in unlawful practices. Investors affected are advised to contact the law firm for potential class action participation.

Tyra Biosciences is currently under investigation for potential securities fraud following its Phase 2 cancer drug trial results. For readers following the health sector, here is Pluang's market snapshot as of Oct 08, 2026 21:12 WIB: out of 128 priced US health-sector stocks, 17 rose and 111 fell. Notable movers include Guardant Health Inc. (GH) at USD 162.30 with a 3.58% decline, Citius Pharmaceuticals Inc. (CTXR) at USD 0.49 with a 3.58% drop and a typical hold time of 16 days on Pluang, and SELLAS Life Sciences Group Inc. (SLS) at USD 10.91 down 3.54%.

More News

Artesian Resources misses Q3 earnings and revenue estimates despite 4.8% revenue growth.

Artesian Resources misses Q3 earnings and revenue estimates despite 4.8% revenue growth.

Artesian Resources Corporation reported Q3 2026 earnings of $0.65 per share, missing the $0.67 estimate and down from $0.68 a year earlier. Revenue rose 4.8% year-over-year to $31.9 million but fell short of the $32.2 million forecast. Net income dec...

Company Fundamentals
Bearish
1 hour ago
US coffee market to reach $32.2B by 2032, driven by specialty coffee and premiumization trends.

US coffee market to reach $32.2B by 2032, driven by specialty coffee and premiumization trends.

The US coffee market is projected to grow from $26.1 billion in 2027 to $32.2 billion by 2032, with a CAGR of 4.32%. Specialty coffee is the fastest-growing segment, expanding at 6.78% CAGR due to rising demand for premium and functional coffee optio...

Market News
Bullish
3 hours ago
BAIC FOTON launches supercharging strategy with new electric trucks and global charging network plans

BAIC FOTON launches supercharging strategy with new electric trucks and global charging network plans

BAIC FOTON unveiled a new supercharging strategy in Beijing, introducing the world's first supercharged light truck AUMARK Z and heavy-duty megawatt trucks. The strategy integrates vehicles, charging stations, grids, and cloud platforms to optimize e...

Market News
Bullish
3 hours ago
BAIC FOTON launches supercharging strategy with new electric trucks to boost global smart energy ecosystem.

BAIC FOTON launches supercharging strategy with new electric trucks to boost global smart energy ecosystem.

BAIC FOTON unveiled its Supercharging Strategy in Beijing, introducing the world's first supercharge-capable light-duty AUMARK Z truck and megawatt-class heavy-duty trucks. This integrated energy management system connects vehicles, charging stations...

Bullish
3 hours ago
BAIC FOTON launches ultra-fast charging strategy and new electric trucks to boost global smart energy ecosystem

BAIC FOTON launches ultra-fast charging strategy and new electric trucks to boost global smart energy ecosystem

BAIC FOTON unveiled a new ultra-fast charging strategy on November 6, 2026, in Beijing, introducing the AUMARK Z small electric truck and large trucks supporting megawatt-level charging. This integrated system connects vehicles, chargers, power grids...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App